Một nghiên cứu của PGS.TS. Lê Quang Huấn
Tài liệu tham khảo
 Fang Hong, Miao Qing Fang, Zhang ShengHua, Cheng Xin, Xiong DongSheng, Zhen YongSu. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin. Life Sciences. China. 2011, 54 (3), pp.255-262.
 Fisher R.I. Overview of non-Hodgkin’s lymphoma: biology, staging, and treatment. Seminars in Oncology. 2003, 30 (2 – 4), pp.3-9.
 Geng S, Feng J, Li Y, Sun Y, Gu X, Huang Y, Wang Y, Kang X, Chang H, and Shen B. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange. Cellular and Molecular Immunology. 2006, 3 (6), pp.439-443.
 Hagemeyer C.E, Muhlen C.V, Elverfeldt D.V, Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thrombosis and Haemostasis. 2009, 101, pp.1012-1019.
 Kipriyanov S.M, Moldenhauer G, Schuhmacher J, Cochlovius B, Vonder Lieth C.W, Matys E.R, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. Molecular Biology. 1999, 293 (1), pp.41-56.
 Lim SH, Beers SA, French RR, Johnson PWM, GlennieMJ and Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010, 95, pp.135-143.
 Reff M.E, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Critical Reviews in Oncology Hematology. 2001, 40, pp.25-35.
 Sambrook J, Russell D.W. Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, New York. 2001. 10. Scott A.M, Allison J.P and Wolchok J.D. Monoclonal antibodies in cancer therapy. Cancer Immunity. 2012, 12, pp.1-8.